Dr Austin Kulasekararaj discusses Phase 3 results of ALXN 1210
Posted on
Dr Austin Kulasekararaj, consultant haematologist Kings College Hospital London, and ALXN 1210 investigator, said, “ALXN1210 could provide an effective alternative choice for treatment of both treatment-naïve PNH patients and also switching patients stably established on eculizumab.”
“The non-inferiority data from the two large phase 3 trials, enrolling over 440 patients, is exciting and encouraging for the PNH community and widens the scope of delivery of anti-complement therapy in the future.”
To read more click here